Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 15/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heteronium SCHEMBL668862 | 0.99 | CHRM3 (0.66) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| Benzopyrronium SCHEMBL2111041 | 0.87 | CHRM3 (0.85) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| Benzopyrronium SCHEMBL916243 | 0.85 | CHRM3 (0.85) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| Parapenzolate SCHEMBL14547205 | 0.80 | CHRM3 (0.73) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL13716300 | 0.80 | CHRM3 (0.68) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL7145497 | 0.80 | CHRM3 (0.68) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL170999 | 0.80 | CHRM3 (0.68) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL7145504 | 0.80 | CHRM3 (0.68) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL13716305 | 0.80 | CHRM3 (0.68) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| Bromide SCHEMBL11483400 | 0.79 | CHRM3 (0.50) | CHRM3CHRM2KCNH2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3902567-A2 | TREATMENT OF RESPIRATORY DISORDERS WITH ARACHIDONATE15-LIPOXYGENASE (ALOX15) INHIBITORS | Regeneron Pharmaceuticals, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200254070-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
| WO-2020139830-A2 | TREATMENT OF RESPIRATORY DISORDERS WITH ARACHIDONATE15-LIPOXYGENASE (ALOX15) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| EP-0412131-A4 | SUBSTANTIALLY DRY CLEANING WIPE | — | 1992-05-20 | — | — | EP | disclosed |
| US-5094770-A | Glycol, cationic surfactant | NORDICO, INC. (US) | 1992-03-10 | — | — | US | disclosed |
| US-5091102-A | Hard surface cleaning system wipe; coating of glycol comopund, cationic surfactant and antiseptic | NORDICO, INC. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0412131-A1 | SUBSTANTIALLY DRY CLEANING WIPE. | SHERIDAN CHRISTOPHER H (US) | 1991-02-13 | — | — | EP | disclosed |
| US-4946617-A | MATRIX OF FIBERS OR FOAM UNIFORMLY COATED WITH A GLYCOL AND A CATIONIC SURFACTANT SOLUTION | NORDICO, INC. (US) | 1990-08-07 | — | — | US | disclosed |
| WO-1990005771-A1 | SUBSTANTIALLY DRY CLEANING WIPE | SHERIDAN CHRISTOPHER H (US) | 1990-05-31 | — | — | WO | disclosed |
| EP-0198034-A1 | PHYSIOLOGICAL MEANS OF ENHANCING TRANSDERMAL DELIVERY OF DRUGS. | KEY PHARMA (US) | 1986-10-22 | — | — | EP | disclosed |
| WO-1986002272-A1 | PHYSIOLOGICAL MEANS OF ENHANCING TRANSDERMAL DELIVERY OF DRUGS | KEY PHARMACEUTICALS, INC. (US) | 1986-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | CHRM3 4310/4885CHRM2 4475/4885KCNH2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.